The UK's drug pricing body has affirmed its earlier decision not to recommend coverage of AstraZeneca and Daiichi Sankyo’s ...

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put ...

The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...